News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)

Abstract

The incidence of skin melanoma is growing globally and in Russia. Also, the proportion of patients with advanced skin melanoma prevails. Introduction into clinical practice of a novel group of immunological drugs (anti-CTLA4 and anti-PD-1) for metastatic melanoma increased the time to disease progression and patients' life expectancy. Prolgolimab is a PD-1 inhibitor, a new domestic drug that is effective and safe in treating metastatic melanoma. The article presents authors' experience with prolgolimab. When used in the first-line treatment of metastatic melanoma, this drug achieved long-term stabilization of the disease. The drug showed good tolerability, including in patients with severe comorbidity.

Keywords

• metastatic melanoma
• immunotherapy
• immune checkpoint inhibitors
• ctla-4
• pd-1
• ipilimumab
• nivolumab
• prolgolimab
• pembrolizumab